Trophogen
Trophogen Inc. specializes in protein engineering to develop patented long-acting, potent, and safe non-immunogenic analogs of glycoprotein hormones and growth factors for human and animal health. Their innovative platform technology addresses multi-billion dollar markets in infertility, egg banking, and cancer treatment, with products ready for clinical trials and market competition.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Recombinant long-acting bovine FSH analog for superovulation
A modified recombinant bovine follicle-stimulating hormone analog designed for long-acting, high potency superovulation and embryo transfer in cattle; developed and licensed to an animal health company.
Recombinant long-acting equine-derived chorionic gonadotropin analog for estrus synchronization
A recombinant analog intended to reduce time to and synchronize estrus in livestock species.
Recombinant long-acting human FSH analog for infertility and egg banking
A modified recombinant human follicle-stimulating hormone analog developed for infertility treatment and elective egg banking with increased potency and extended duration.
Recombinant long-acting human TSH analog for thyroid imaging and treatment
A recombinant human thyroid-stimulating hormone analog intended for imaging and therapeutic applications in thyroid cancer.
VEGF analogs for targeted imaging of undifferentiated thyroid cancer
Engineered vascular endothelial growth factor analogs developed as targeted imaging agents for detection of undifferentiated thyroid tumors; development supported by an NIH/NCI SBIR award.
Recombinant long-acting bovine FSH analog for superovulation
A modified recombinant bovine follicle-stimulating hormone analog designed for long-acting, high potency superovulation and embryo transfer in cattle; developed and licensed to an animal health company.
Recombinant long-acting equine-derived chorionic gonadotropin analog for estrus synchronization
A recombinant analog intended to reduce time to and synchronize estrus in livestock species.
Recombinant long-acting human FSH analog for infertility and egg banking
A modified recombinant human follicle-stimulating hormone analog developed for infertility treatment and elective egg banking with increased potency and extended duration.
Recombinant long-acting human TSH analog for thyroid imaging and treatment
A recombinant human thyroid-stimulating hormone analog intended for imaging and therapeutic applications in thyroid cancer.
VEGF analogs for targeted imaging of undifferentiated thyroid cancer
Engineered vascular endothelial growth factor analogs developed as targeted imaging agents for detection of undifferentiated thyroid tumors; development supported by an NIH/NCI SBIR award.
Services
Negotiated exclusive licensing and purchase agreements to transfer development and commercialization rights of recombinant animal reproduction biologics to external partners.
Preclinical development and regulatory preparation to support IND filing and initiation of clinical trials for engineered protein therapeutics and imaging agents.
Negotiated exclusive licensing and purchase agreements to transfer development and commercialization rights of recombinant animal reproduction biologics to external partners.
Preclinical development and regulatory preparation to support IND filing and initiation of clinical trials for engineered protein therapeutics and imaging agents.
Expertise Areas
- Protein engineering for biologics
- Biologic therapeutic and diagnostic development
- Reproductive biotechnology (human and veterinary)
- Targeted molecular imaging agent development
Key Technologies
- Recombinant protein expression
- Protein engineering for potency and half-life extension
- De-immunization of therapeutic proteins
- Targeted molecular imaging agents
News & Updates
On July 7th, 2015, Trophogen announced it received a $756,000 SBIR award from NIH/NCI to develop VEGF analogs for thyroid cancer imaging.
On June 2nd, 2015, Trophogen announced a licensing and purchase agreement with Zoetis Inc. for rbFSH analog for animal health reproduction.
On July 7th, 2015, Trophogen announced it received a $756,000 SBIR award from NIH/NCI to develop VEGF analogs for thyroid cancer imaging.
On June 2nd, 2015, Trophogen announced a licensing and purchase agreement with Zoetis Inc. for rbFSH analog for animal health reproduction.